FibroGen, Inc. (FGEN)

Market Cap	2.29B
Revenue (ttm)	122.91M
Net Income (ttm)	-361.56M
Shares Out	93.96M
EPS (ttm)	-3.89
PE Ratio	n/a
Forward PE	61.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,114,533
Open	23.60
Previous Close	23.60
Day's Range	23.44 - 24.58
52-Week Range	7.81 - 24.58
Beta	0.72
Analysts	Buy
Price Target	17.95 (-26.4%)
Earnings Date	Feb 27, 2023

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human mon...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 566
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN

Financial Performance

In 2021, FibroGen's revenue was $235.31 million, an increase of 33.46% compared to the previous year's $176.32 million. Losses were -$290.02 million, 53.2% more than in 2020.

Analyst Forecast

According to 13 analysts, the average rating for FGEN stock is "Buy." The 12-month stock price forecast is $17.95, which is a decrease of -26.40% from the latest price.

Price Target

$17.95

(-26.40% downside)

Analyst Consensus: Buy